IP Library › Granted Patent US 11,654,212
Granted Patent B2
US 11,654,212 · App. 15/558,787 · Granted May 23, 2023

Injectable collagen suspensions, the preparation method thereof, and the uses thereof, particularly for forming dense collagen matrices

Inventors: Nadine Nassif (Paris, FR); Francisco Miguel Moreira Martins Fernandes (Paris, FR); Cedric Boissiere (Villebon sur Yvette, FR); Clement Sanchez (Bures-sur-Yvette, FR); Marie-Madeleine Giraud-Guille (Paris, FR)
Assignees: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
A61L27/24A61K8/022A61K8/025A61K8/14A61K8/606A61K8/65A61K38/39A61L27/50A61L27/52A61L27/54A61Q19/08C08J3/122A61K2800/412A61K2800/654A61K2800/91A61L2300/232A61L2300/236A61L2300/252A61L2300/402A61L2300/428A61L2400/06A61L2430/06A61L2430/34A61L2430/38C08J2389/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,654,212
App. No.
15/558,787
Granted
May 23, 2023
Kind
B2
Abstract

Disclosed is the preparation of injectable collagen suspensions, to the method for preparing the suspensions, and to the uses thereof, particularly for forming dense collagen matrices.

Claims (18)

1. An injectable suspension consisting of a powdered composition in an aqueous solution formed of water and acid or of a saline phosphate buffer,

wherein said powdered composition consists of spherical or spheroidal solid particles consisting of more than 90% by mass of non-denatured and uncrosslinked collagen, and less than 10% by mass of an aqueous solution formed of water and acid,

wherein a total collagen concentration is in a range of 20 to 200 mg per ml of suspension,

wherein a diameter of said spherical or spheroidal solid particles is in a range of 0.25 μm to 10 μm,

wherein the suspension forms dense fibrillar collagen matrices in vivo by assembly of collagen molecules of which the intermolecular distance is less than 10 nm, after being contacted with a physiological medium.

2. A cosmetic composition containing a suspension according to claim 1 , said cosmetic composition further comprising one or more additives selected from anaesthetics, hyaluronic acid, elastins, vitamins and platelet rich plasma, ions, precursors of a mineral phase, proteoglycans, glycosaminoglycan, and non-fibrillar collagen types.

3. A pharmaceutical composition containing a suspension according to claim 1 .

4. An injectable suspension consisting of a powdered composition in an acid-soluble collagen acidic aqueous solution,

wherein said powdered composition consists of spherical or spheroid solid particles consisting of more than 99% by mass of non-denatured and uncrosslinked collagen, and less than 1% by mass of an aqueous solution formed of water and acid,

wherein a diameter of said spherical or spheroid solid particles is in a range of 0.25 μm to 10 μm,

wherein the total collagen concentration is greater than 20 mg per ml of suspension, and

wherein the suspension forms dense fibrillar collagen matrices in vivo by assembly of collagen molecules of which the intermolecular distance is less than 10 nm, after being contacted with a physiological medium.

5. An injectable suspension consisting of a powdered composition in an acid-soluble collagen acidic aqueous solution,

wherein said powdered composition consists of spherical or spheroid solid particles consisting of more than 99% by mass of non-denatured and uncrosslinked collagen, and less than 1% by mass of an aqueous solution formed of water and acid,

wherein a diameter of said spherical or spheroid solid particles is in a range of 0.25 μm to 10 μm,

wherein the total collagen concentration is greater than 100 mg per ml of suspension, and

wherein the suspension forms dense fibrillar collagen matrices in vivo by assembly of collagen molecules of which the intermolecular distance is less than 10 nm, after being contacted with a physiological medium.

6. The suspension according to claim 1 , wherein the acid present in said powdered composition is acetic acid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2018
From: NASSIF, NADINE; MOREIRA MARTINS FERNANDES, FRANCISCO MIGUEL; BOISSIERE, CEDRIC; SANCHEZ, CLEMENT; GIRAUD-GUILLE, MARIE-MADELEINE
To: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 045671/0778 →
Priority Claims (1)
FR 1552200 · Mar 17, 2015 · national
Continuity (1)
Related Publication 20180071430A1 · Mar 15, 2018